Movement Alert|CRISPR Therapeutics AG Intraday Rise 5.28%, clinical pipeline updates and a reiterated Buy rating support the rebound

Market Focus
11/18

On November 18, CRISPR Therapeutics AG rose 5.28% in Regular Trading, trading at $42.01 per share, with turnover of $9.2124 million.

The identifiable catalyst was continued market digestion of recent clinical updates for CTX310 and zugo-cel, alongside an analyst reiteration of a Buy rating with an $80 price target, which together helped support the rebound.

Recent company disclosures showed Phase 1b data for CTX310 in severe hypertriglyceridemia, where a single-course treatment produced mean reductions of 65% in ANGPTL3 and 63% in triglycerides. Separately, early autoimmune data for zugo-cel showed an 83% clinical response rate at Month 3 in systemic sclerosis patients receiving standard lymphodepletion. These developments came after the company’s latest quarterly EPS of negative $1.15 missed consensus, while revenue of $12.669 million exceeded expectations, underscoring that the latest share move is being driven primarily by pipeline news and external rating support rather than earnings alone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10